Balchem (NASDAQ:BCPC - Get Free Report) is expected to be announcing its earnings results before the market opens on Friday, February 21st. Analysts expect the company to announce earnings of $1.11 per share and revenue of $239.96 million for the quarter. Investors that wish to register for the company's conference call can do so using this link.
Balchem Stock Up 1.0 %
Shares of NASDAQ BCPC traded up $1.68 during trading on Monday, hitting $164.82. 131,072 shares of the company traded hands, compared to its average volume of 114,008. The business's fifty day moving average is $163.23 and its 200 day moving average is $169.45. Balchem has a fifty-two week low of $137.69 and a fifty-two week high of $186.03. The firm has a market capitalization of $5.36 billion, a price-to-earnings ratio of 44.31, a P/E/G ratio of 4.42 and a beta of 0.69. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.90 and a current ratio of 2.98.
Balchem Increases Dividend
The business also recently disclosed an annual dividend, which was paid on Friday, January 17th. Stockholders of record on Thursday, December 26th were issued a dividend of $0.87 per share. The ex-dividend date was Thursday, December 26th. This represents a dividend yield of 0.4%. This is a positive change from Balchem's previous annual dividend of $0.79. Balchem's dividend payout ratio is currently 23.39%.
Wall Street Analyst Weigh In
BCPC has been the subject of several recent research reports. HC Wainwright boosted their target price on shares of Balchem from $185.00 to $190.00 and gave the stock a "buy" rating in a research report on Monday, November 4th. StockNews.com raised shares of Balchem from a "hold" rating to a "buy" rating in a research report on Monday, October 28th.
View Our Latest Research Report on BCPC
About Balchem
(
Get Free Report)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Recommended Stories
Before you consider Balchem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Balchem wasn't on the list.
While Balchem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
